What we are studying
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group study to find out whether an investigational drug called aducanumab has the potential to be a helpful treatment that slows down the disease progression of early Alzheimer’s Disease (AD). This drug will be compared to placebo. During this study we will evaluate the safety (side effects), and find out more about aducanumab.
Participants may receive up to $1,600 if all visits are completed over 18 months.
Screening 1: $25. Screening 2: $25. Screening MRI: $25. 20 Infusion visits: $50 each. 2 optional lumbar puncture: $100 each. 7 MRI scans: $25 each.